Copyright
©The Author(s) 2020.
World J Clin Cases. Nov 26, 2020; 8(22): 5576-5588
Published online Nov 26, 2020. doi: 10.12998/wjcc.v8.i22.5576
Published online Nov 26, 2020. doi: 10.12998/wjcc.v8.i22.5576
Figure 1 Flow chart of study inclusion.
T2D: Type 2 diabetes; DPP4i: Dipeptidyl peptidase-4 inhibitors.
- Citation: Zhou JH, Wu B, Wang WX, Lei F, Cheng X, Qin JJ, Cai JJ, Zhang X, Zhou F, Liu YM, Li HM, Zhu LH, She Z, Zhang X, Yang J, Li HL. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19. World J Clin Cases 2020; 8(22): 5576-5588
- URL: https://www.wjgnet.com/2307-8960/full/v8/i22/5576.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i22.5576